Aldebaran Financial’s Biogen BIIB Stock Holding History

Aldebaran Financial’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-920	Closed	-$290K	–	114
2014 Q2	$290K	Buy	+920	New	+$277K	0.23%	99

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Aldebaran Financial's BIIB Position: Q3 2014 in Review

Aldebaran Financial sold out of Biogen (BIIB) in Q3 2014, closing a stake of 920 shares — an estimated $290K sold.

Aldebaran Financial first reported a position in BIIB in Q2 2014 and held it in 1 quarter. The position peaked at $290K in Q2 2014. 818 funds tracked by Wall St. Rank hold BIIB as of Q3 2014.

Aldebaran Financial reported no remaining Biogen position as of Q3 2014 after selling out during the quarter.
Aldebaran Financial sold 920 Biogen shares in Q3 2014, an estimated $290K.
Aldebaran Financial first reported a position in Biogen in Q2 2014 and held it in 1 quarter.
Aldebaran Financial's Biogen position peaked at $290K in Q2 2014.
818 funds tracked by Wall St. Rank held Biogen as of Q3 2014.

Based on Aldebaran Financial's 13F filing for Q3 2014, filed 14 Nov 2014.